Physician profile
Kathryn Bizzak
NPI 1326629742
$9,151.32
in general payments reported to CMS, 2019-2025
39 companies · $1,745 in 2025
The $1,745 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $27.91 · 2023: $1,876 · 2024: $5,503 · 2025: $1,745.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,824 · Consulting Fee: $1,745 · Travel and Lodging: $1,554.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,824.35 |
| Consulting Fee | $1,745.00 |
| Travel and Lodging | $1,554.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $3,851.87 | 2023-2025 | Epclusa, Biktarvy |
| Abbvie INC. | $948.67 | 2023-2025 | |
| Viiv Healthcare Company | $739.45 | 2023-2025 | Dovato, Cabenuva, Apretude |
| Organogenesis INC. | $416.36 | 2024-2025 | Novachor, Nushield, Affinity |
| Amgen INC. | $380.72 | 2023-2025 | Prolia, Evenity, Prolia |
| Paratek Pharmaceuticals, INC. | $358.58 | 2023-2025 | Nuzyra |
| Novo Nordisk INC | $281.93 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Smith+Nephew, INC. | $233.81 | 2023-2025 | Grafix Pl, Stravix, Oasis |
| Pfizer INC. | $198.09 | 2023-2025 | |
| Insmed, INC. | $192.46 | 2023-2025 | Arikayce, Brinsupri |
| Merck Sharp & Dohme LLC | $141.19 | 2023-2025 | Dificid, Pifeltro, Delstrigo |
| Indivior INC. | $140.55 | 2023-2025 | Sublocade |
| Theratechnologies INC. | $94.29 | 2023 | Trogarzo, Egrifta |
| Nestle Healthcare Nutrition INC. | $90.63 | 2023 | |
| Urgo Medical North America, LLC | $83.07 | 2023-2024 | Vashe Wound Solution 250 Ml (8.5 Fl Oz) Flip Top Cap, Urgok2 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $69.83 | 2021-2024 | Mounjaro, Omvoh, Zepbound |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $68.50 | 2024-2025 | Xifaxan, Trulance |
| Sumitomo Pharma America, INC. | $64.25 | 2023-2024 | Gemtesa |
| Exact Sciences Corporation | $64.14 | 2023-2024 | Cologuard Collection Kit |
| Astellas Pharma US INC | $63.54 | 2025 | Veozah |
| Tactile Systems Technology INC | $57.61 | 2024 | Entre Plus, Flexitouch Plus |
| Ferring Pharmaceuticals INC. | $55.57 | 2023-2024 | Rebyota |
| Eisai INC. | $54.72 | 2023-2024 | |
| Stryker Corporation | $51.68 | 2025 | Clottriever Bold Catheter |
| Aimmune Therapeutics, INC. | $50.93 | 2025 | Vowst |
| Grifols USA, LLC | $40.76 | 2025 | Xembify, Prolastin-C Liquid |
| Glaxosmithkline, LLC. | $40.57 | 2023-2024 | Shingrix, Arexvy, Bexsero |
| Lundbeck LLC | $38.66 | 2023 | Vyepti |
| Daiichi Sankyo INC. | $37.30 | 2023-2024 | Injectafer |
| Cumberland Pharmaceuticals, INC. | $37.07 | 2023 | Vibativ |
| Astrazeneca Pharmaceuticals LP | $35.84 | 2023 | Evusheld |
| Hologic Sales and Service, LLC | $31.18 | 2025 | Thinprep 2000 Processor, Aptima |
| Ardelyx, INC. | $23.03 | 2024 | Ibsrela |
| Mimedx Group, INC. | $21.76 | 2024 | |
| Braeburn INC. | $19.93 | 2024 | Brixadi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $19.05 | 2025 | Caplyta |
| Csl Behring | $18.77 | 2024 | Hizentra |
| Bioventus LLC | $17.93 | 2023 | |
| Pharming Healthcare, INC. | $17.03 | 2024 | Ruconest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathryn Bizzak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.